Life Sciences N.V. Atai Sells 2,660,000 Shares of COMPASS Pathways plc (NASDAQ:CMPS) Stock

COMPASS Pathways plc (NASDAQ:CMPS) major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the firm’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $6.05, for a total value of $16,093,000.00. Following the completion of the transaction, the insider now owns 6,905,774 shares of the company’s stock, valued at approximately $41,779,932.70. The sale was disclosed in a document filed with the SEC, which is available through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

COMPASS Pathways Stock Performance

CMPS stock traded down $0.10 during mid-day trading on Friday, hitting $6.81. 236,067 shares of the company were exchanged, compared to its average volume of 540,680. The business has a 50 day simple moving average of $7.16 and a 200-day simple moving average of $7.65. The company has a current ratio of 12.03, a quick ratio of 12.03 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $465.74 million, a PE ratio of -2.87 and a beta of 2.27. COMPASS Pathways plc has a 1-year low of $5.01 and a 1-year high of $12.75.

COMPASS Pathways (NASDAQ:CMPS) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.03). During the same period in the previous year, the business posted ($0.62) EPS. On average, equities analysts forecast that COMPASS Pathways plc will post -2.35 earnings per share for the current year.

Institutional Investors Weigh In On COMPASS Pathways

A number of hedge funds and other institutional investors have recently made changes to their positions in CMPS. Quest Partners LLC acquired a new stake in shares of COMPASS Pathways in the fourth quarter valued at approximately $33,000. Blue Trust Inc. bought a new stake in shares of COMPASS Pathways during the second quarter worth $81,000. Kennedy Capital Management LLC bought a new stake in shares of COMPASS Pathways during the first quarter worth $139,000. Tidal Investments LLC grew its stake in shares of COMPASS Pathways by 43.6% during the first quarter. Tidal Investments LLC now owns 19,082 shares of the company’s stock worth $159,000 after buying an additional 5,795 shares during the last quarter. Finally, Fore Capital LLC bought a new stake in shares of COMPASS Pathways in the second quarter worth $181,000. 46.19% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CMPS has been the subject of several analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of COMPASS Pathways in a report on Monday, September 9th. Royal Bank of Canada restated an “outperform” rating and issued a $23.00 price objective on shares of COMPASS Pathways in a report on Tuesday, September 10th. Canaccord Genuity Group cut their target price on shares of COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, August 2nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $120.00 target price on shares of COMPASS Pathways in a research note on Friday, August 23rd. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, COMPASS Pathways currently has an average rating of “Buy” and an average price target of $47.40.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.